Jubilant Life Sciences’ arm signs drug discovery agreement with Orion Corporation

13 May 2014 Evaluate

In a bid to develop medicines in the neuroscience therapeutic area, Jubilant Life Sciences has entered into drug discovery pact with Finland’s Orion Corporation. The company has entered into the agreement through its Bengaluru-based subsidiary Jubilant Biosys. The research deal is aimed at developing drug that can benefit large population with unmet needs in the pain management area.

Under the royalty-based alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights, while Jubilant will offer integrated drug discovery services across synthetic and medicinal chemistry including scale up and pre-clinical facilities.

Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.

Jubilant Pharmova Share Price

1065.05 2.00 (0.19%)
23-Dec-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1341.60
Cipla 1476.45
Lupin 2168.25
Zydus Lifesciences 972.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.